Amgen

AGREEMENT GRADE
f
Fortune 500 Rank
OWLER CEO APPROVAL RATING
51/100
GLASSDOOR RATING
4.1
CEO
Robert A. Bradway

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. In 2013, the company’s largest selling product lines were Neulasta/Neupogen, two closely related drugs used to prevent infections in patients undergoing cancer chemotherapy; and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA.

AG Sources

Court granted defendants’ motion to dismiss action and compel arbitration, adopting the magistrate judge’s recommendation that the plaintiff failed to opt-out of the arbitration agreement in question and that the agreement covered the claims asserted. -Alvarez v. Amgen Manufacturing Limited, September 2017

Magistrate judge recommended the court grant defendant’s motion to dismiss and compel arbitration, finding the parties had entered into a valid arbitration agreement during the course of employment. Court rejected plaintiff’s argument that after initially signing an arbitration agreement in 2006, she signed a new agreement in 2014 in which she opted out of the arbitration agreement, constituting a novation. -Alvarez v. Amgen Manufacturing Limited, August 2017

Upper management lacks diversity. Rarely promotes opportunities for women and minorities. If they discriminate you can’t sue due to the arbitration agreement you must sign before working there. -Glassdoor Employee Review (2016)

COMMENTS

Links

Company Website
Career Opportunities

POST A COMMENT